Skip to main content
Woman, living with factor XIII A-subunit deficiency, sitting next to her garden


Vanessa has congenital FXIII deficiency

Novo Nordisk can help your patients get the treatment and support they want

Novo Nordisk has a variety of resources and support to help your patients get the most out of their treatment with Tretten®


 



 

Help them get treatment

Patients with congenital FXIII A-subunit deficiency may be able to get help with treatment costs through Novo Nordisk’s Hemophilia and Rare Bleeding Disorder Product Assistance Programs.


 

Novo Nordisk Lab Program

Novo Nordisk sponsors a laboratory program for patients prescribed Tretten® to confirm congenital FXIII A-subunit deficiency.


 

Trial Prescription Program

Qualifying patients can receive a trial prescription for 2 doses of Tretten®.a To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.

aPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.


 

Co-pay Assistance Program

Eligible patients receive up to $12,000/year toward their co-pay for a Novo Nordisk factor product.b

Your patient may be eligible if they:

  • Have been prescribed a Novo Nordisk factor product
  • Are currently privately/commercially insured

bNovo Nordisk Hemophilia and Rare Bleeding Disorders Copay/Coinsurance Terms and Conditions:
Enrolled patients are eligible for up to $12,000 in co-pay/coinsurance assistance per calendar year for each NNI hemophilia or rare bleeding disorder product. Assistance is retroactive to 60 days. Patients must be commercially insured and may not be participating in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance. Uninsured, cash-paying patients are not eligible to participate. Patients are eligible to receive co-pay/coinsurance assistance on an annual basis (12 months). Offer good only in the USA, Puerto Rico, Guam, Saipan, and Virgin Islands with participating pharmacies and cannot be redeemed at government-subsidized clinics. Void where taxed, restricted, or prohibited by law. Absent a change in Massachusetts law, effective July 1, 2019, the Savings Card will no longer be valid for residents of Massachusetts. Patient is responsible for complying with any insurance carrier co-payment disclosure requirements, including disclosing any savings received from this program. Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms. This is not an insurance program. Novo Nordisk reserves the right to rescind, revoke, or amend this offer without notice at any time. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible. Must have a current prescription for an FDA-approved indication.


 

Patient Assistance Program

Novo Nordisk provides factor products to qualifying patients at no charge.

Your patient may be eligible if they:

  • Have been prescribed a Novo Nordisk factor product
  • Are currently uninsured
  • Have no options for alternate coverage
  • Have a gap in coverage

Encourage such patients to submit a Product Assistance Program application or call 1-844-668-6732 to learn more.


 



 

Two ways to help them feel even more supported

NovoSecure™

NovoSecure™, the program that provides support to your patients, regardless of treatment choice.
 

Novo Nordisk Representatives

Your Tretten® patients have access to Novo Nordisk Representatives—excellent sources of information and support.


 


Selected Important Safety Information

Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.

Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Indications and Usage

Tretten® (Coagulation Factor XIII A-Subunit [Recombinant]) is indicated for routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.

Tretten® is not for use in patients with congenital Factor XIII B-subunit deficiency.

Important Safety Information

Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the exicipients.

Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Thromboembolic complications may occur. Monitor patients with conditions that predispose to thrombosis for signs and symptoms of thrombosis after administration of Tretten®.

Inhibitory antibodies may occur with Tretten®. Patients with inhibitory antibodies may manifest as an inadequate response to treatment. If expected plasma FXIII activity levels are not attained, or if breakthrough bleeding occurs while receiving prophylaxis, perform an assay that measures FXIII inhibitory antibody concentrations.

The most common adverse reactions reported in clinical trials (≥1%) were headache, pain in the extremities, pain at injection site, and increase in fibrin D dimer levels. 

Thrombosis may occur if Tretten® is administered concomitantly with Factor VIIa.

There are no adequate and well-controlled studies using Tretten® in pregnant women to determine whether there is a drug-associated risk. Animal reproduction studies have not been conducted with Tretten®.

Please click here for Tretten® Prescribing Information.